References
- 1. J. K. Taubenberger and D. M. Morens, 1918 Influenza: the mother of all pandemic, Emerg. Infect. Dis. 12 (2006) 15-22; DOI: 10.3201/eid1201.050979.
- 2. P. Auewarakul, O. Suptawiwat, A. Kongchanagul, C. Sangma, Y. Suzuki, K. Ungchusak, S. Louisirirotchanakul, H. Lerdsamran, P. Pooruk, A. Thitithanyanont, C. Pittayawonganon, C.-T. Guo, H. Hiramatsu, W. Jampangern, S. Chunsutthiwat and P. Puthavathana, An avian influenza H5N1 virus that binds to a human-type receptor, J. Virol. 81 (2007) 9950-9955; DOI: 10.1128/ JVI.00468-07.
- 3. I. V. Alymova, A. Portner, V. P. Mishin, J. A. McCullers, P. Freiden and G. L. Taylor, Receptor- -binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein, Glycobiology 22 (2012) 174-180; DOI: 10.1093/glycob/cwr112.
- 4. S.-Q. Wang, Q.-S. Du, R.-B. Huang, D.-W. Zhang and K.-C. Chou, Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus, Biochem. Biophys. Res. Commun. 386 (2009) 432-436; DOI: 10.1016/j.bbrc.2009.06.016.
- 5. H. T. Nguyen, T. G. Sheu, V. P. Mishin, A. I. Klimov and L. V Gubareva, Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays, Antimicrob. Agents Chemother. 54 (2010) 3671-3677; DOI: 10.1128/ AAC.00581-10.
- 6. N. J. Dharan, L. V. Gubareva, J. J. Meyer, M. Okomo-Adhiambo, R. C. McClinton, S. A. Marshall, K. St George, S. Epperson, L. Brammer, A. I. Klimov, J. S. Bresee and A. M. Fry, Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States, JAMA 301 (2009) 1034-1041; DOI: 10.1001/jama.2009.294.
- 7. T. Kolomin, M. Shadrina, P. Slominsky, S. Limborska and N. Myasoedov, A new generation of drugs: Synthetic peptides based on natural regulatory peptides, Neurosci. Med. 4 (2013) 223-252; DOI: 10.4326/nm.2013.44035.
- 8. C. D. Fjell, J. A. Hiss, R. E. W. Hancock and G. Schneider, Designing antimicrobial peptides: form follows function, Nat. Rev. Drug Discov. 11 (2012) 37-51; DOI: 10.1038/nrd3591.
- 9. S. Riedl, D. Zweytick and K. Lohner, Membrane-active host defense peptides - challenges and perspectives for the development of novel anticancer drugs, Chem. Phys. Lipids 164 (2011) 766-781; DOI: 10.1016/j.chemphyslip.2011.09.004.
- 10. P. Vlieghe, V. Lisowski, J. Martinez and M. Khrestchatisky, Synthetic therapeutic peptides: science and market, Drug. Disc. Today 15 (2010) 40-56; DOI: 10.1016/j.drudis.2009.10.009.
- 11. R. Benigni and C. Bossa, Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology, Mutat. Res. 659 (2008) 248-261; DOI: 10.1016/j.mrrev.2008.05.003.
- 12. U. S. F. Tambunan, N. Amri and A. A. Parikesit, In silico design of cyclic peptides as influenza virus, a subtype H1N1 neuraminidase inhibitor, African J. Biotechnol. 11 (2012) 11474-11491; DOI: 10.5897/AJB11.4094.
- 13. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46 (2001) 3-26.
- 14. S.-L. Du, H. Pan, W.-Y. Lu, J. Wang, J. Wu and J.-Y. Wang, Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats, J. Pharmacol. Exp. Ther. 322 (2007) 560-568; DOI: 10.1124/jpet.107.122481.
- 15. T. R. White, C. M. Renzelman, A. C. Rand, T. Rezai, C. M. McEwen, V. M. Gelev, R. A. Turner, R. G. Linington, S. S. F. Leung, A. S. Kalgutkar, J. N. Bauman, Y. Zhang, S. Liras, D. A. Price, A. M. Mathiowetz, M. P. Jacobson and R. S. Lokey, On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds, Nat. Chem. Biol. 7 (2011) 810-817; DOI: 10.1038/nchembio. 664.
- 16. M. Brvar, A. Perdih, M. Renko, G. Anderluh, D. Turk and T. Solmajer, Structure-based discovery of substituted 4,5’-bithiazoles as novel DNA gyrase inhibitors, J. Med. Chem. 55 (2012) 6413-6426; DOI: 10.1021/jm300395d.
- 17. C. Liao, M. Sitzmann, A. Pugliese and M. C. Nicklaus, Software and resources for computational medicinal chemistry, Future Med. Chem. 3 (2011) 1057-1085; DOI: 10.4155/fmc.11.63.
- 18. D. L. Wheeler, T. Barrett, D. A. Benson, S. H. Bryant, K. Canese, V. Chetvernin, D. M. Church, M. DiCuccio, R. Edgar, S. Federhen, L. Y. Geer, Y. Kapustin, O. Khovayko, D. Landsman, D. J. Lipman, T. L. Madden, D. R. Maglott, J. Ostell, K. D. Pruitt, G. D. Schuler, L. M. Schriml, E. Sequeira, S. T. Sherry, K. Sirotkin, A. Souvorov, G. Starchenko, T. O. Suzek, R. Tatusov, T. A. Tatusova, L. Wagner and E. Yaschenko, Database resources of the National Center for Biotechnology Information, Nucl. Acids Res. 35 (2007) D5-D12; DOI: 10.1093/nar/gkl1031.
- 19. U. S. F. Tambunan, R. Harganingtyas and A. A. Parikesit, In silico modification of (1R, 2R, 3R, 5S)-(-)-isopinocampheylamine as inhibitors of M2 proton channel in Influenza A virus subtype H1N1, using the molecular docking approach, Trends Bioinform. 5 (2012) 25-46; DOI: 10.3923/ tb.2012.25.46.
- 20. U. S. F. Tambunan, N. Bramantya and A. A. Parikesit, In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC), BMC Bioinformatics 12 (Suppl. 13) (2011) S23-S38; DOI:10.1186/1471-2105-12-S13-S23.
- 21. R. Benigni and C. Bossa, Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology, Mutat. Res. 659 (2008) 248-261; DOI: 10.1016/j.mrrev.2008.05.003.
- 22. T. Sander, J. Freyss, M. von Korff, J. R. Reich and C. Rufener, OSIRIS, an entirely in-house developed drug discovery informatics system, J. Chem. Inf. Model. 49 (2009) 232-246; DOI: 10.1021/ ci800305f.
- 23. D. Lagorce, O. Sperandio, H. Galons, M. A. Miteva and B. O. Villoutreix, FAF-drugs2: free ADME/ tox filtering tool to assist drug discovery and chemical biology projects, BMC Bioinformatics 9 (2008) 396-405; DOI: 10.1186/1471-2105-9-396.
- 24. A. D. MacKerell, N. Banavali and N. Foloppe, Development and current status of the CHARMM force field for nucleic acids, Biopolymers 56 (2000) 257-265; DOI: 10.1002/1097-0282 (2000)56:4< 257::AID-BIP10029>3.0.CO;2-W.
- 25. Y. Shen, M. K. Gilson and B. Tidor, Charge optimization theory for induced-fit ligands, J. Chem. Theory Comput. 8 (2012) 4580-4592; DOI: 10.1021/ct200931c.
- 26. J. R. Williams, A. L. Khandoga, P. Goyal, J. I. Fells, D. H. Perygin, W. Siess, A. L. Parrill, G. Tigyi and Y. Fujiwara, Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation, J. Biol. Chem. 284 (2009) 17304-17319; DOI: 10.1074/jbc. M109.003194.
- 27. G. L. Warren, C. W. Andrews, A.-M. Capelli, B. Clarke, J. LaLonde, M. H. Lambert, M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, J. M. Woolven, C. E. Peishoff and M. S. Head, A critical assessment of docking programs and scoring functions, J. Med. Chem.49 (2006) 5912-5931; DOI: 10.1021/jm050362n.
- 28. Y. Modis, S. Ogata, D. Clements and S. C. Harrison, A ligand-binding pocket in the dengue virus envelope glycoprotein, Proc. Natl. Acad. Sci. USA 100 (2003) 6986-6991; DOI: 10.1073/pnas. 0832193100.
- 29. M. Takano, T. P. Terada and M. Sasai, Unidirectional Brownian motion observed in an in silico single molecule experiment of an actomyosin motor, Proc. Natl. Acad. Sci. USA 107 (2010) 7769-7774; DOI: 10.1073/pnas.0911830107.
- 30. S. Rogers, R. Wells and M. Rechsteiner, Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis, Science 234 (1986) 364-368, DOI: 10.1126/science.2876518.